

A composite image for a NeVap advertisement. The left side shows a patient in a hospital bed with a ventilator, and a man looking down at the patient. The right side shows a NeVap endotracheal tube against a blue background. Text is overlaid on the bottom left of the image.

Ventilator Associated Pneumonia is the most common and deadly ICU acquired infection

**Protect What Matters Most**

Learn why NeVAP solution will work for your hospital  
[www.nevap.co](http://www.nevap.co)

**NEVAP**  
SAVING LIVES | SAVING COSTS

## NeVap Aspire Subglottic Suction Endotracheal Tubes

- ↓ Mechanical Ventilation time
- ↓ ICU stay
- ↓ Cost \$1,936-\$8,048/patient



## NeVap Inc

NeVap established in 2014, focuses on high impact clinician focused products that improve clinical outcomes and decrease costs. The NeVap Aspire Subglottic Suction Endotracheal tube is the only multi-port endotracheal tube with significantly better fluid recovery in all clinical settings. The device is being utilized in the Operating, Emergency, & Critical Care settings all around the United States and European Union where the device is replacing poor performing subglottic suction endotracheal tube.

## Proof

In a 2019, UCSF conducted a controlled simulation on the NeVap Aspire Subglottic Suction Endotracheal Tube. The NeVap breathing tube was conclusively found to be **10-15X** more effective when compared to single port subglottic suction tubes.

